Journal of Neurology

, Volume 258, Issue 12, pp 2248–2253 | Cite as

Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C)

  • Esteban Muñoz
  • Alex Iranzo
  • Sebastian Rauek
  • Francisco Lomeña
  • Judith Gallego
  • Doménec Ros
  • Joan Santamaría
  • Eduardo Tolosa
Original Communication

Abstract

Nigrostriatal involvement is considered an additional feature in the new consensus criteria for the diagnosis of the cerebellar variant of multiple system atrophy (MSA-C). However, so far, only a few studies, which include a relative small number of patients, give support to this criterion. Our objective was to assess nigrostriatal dopaminergic innervation in patients with MSA-C without parkinsonism by use of dopamine transporter single photon emission computed tomography (DAT SPECT). Thirteen patients that fulfilled criteria for possible or probable MSA-C and presented no parkinsonian signs, and 12 age-matched healthy controls underwent (123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane ([123I]FP-CIT) SPECT. Patients were also evaluated through the Unified Multiple System Atrophy Rating Scale (UMSARS) and brain magnetic resonance imaging (MRI). The mean duration of the cerebellar syndrome was 3.8 ± 1.7 years. DAT SPECT showed a significant decrease of striatal [123I]FP-CIT uptake ratios in patients (p < 0.001). Radiotracer uptake reduction was 21% in the entire striatum, 19% in putamen, and 24% in caudate nuclei. Striatal binding ratios were within the normal range in 3 patients. We did not find correlation between striatal uptake and disease duration, age of patients, UMSARS-II score, and pontine diameter. [123I]FP-CIT SPECT shows that most but not all MSA-C patients without parkinsonism have subclinical nigrostriatal dopaminergic denervation which is not related to disease duration, cerebellar dysfunction, or pontine atrophy.

Keywords

Multiple system atrophy MSA-C Dopamine transporter SPECT Nigrostriatal dopaminergic denervation 

References

  1. 1.
    Stefanova N, Bücke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178PubMedCrossRefGoogle Scholar
  2. 2.
    May S, Gilman S, Sowell BB et al (2007) Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 22:2371–2377PubMedCrossRefGoogle Scholar
  3. 3.
    Yabe I, Soma H, Takei A et al (2006) MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci 249:115–121PubMedCrossRefGoogle Scholar
  4. 4.
    Gilman S, Low PA, Quinn N et al (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94–98PubMedCrossRefGoogle Scholar
  5. 5.
    Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676PubMedCrossRefGoogle Scholar
  6. 6.
    Brooks DJ, Seppi K (2009) Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 24:949–964PubMedCrossRefGoogle Scholar
  7. 7.
    Wenning GK, Tison F, Seppi K et al (2004) Development and validation of the Unified Multiple System Atrophy Rating Scales (UMSARS). Mov Disord 19:1391–1402PubMedCrossRefGoogle Scholar
  8. 8.
    Warmuth-Metz M, Naumann M, Csoti I, Solymosi L (2001) Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Arch Neurol 58:1076–1079PubMedCrossRefGoogle Scholar
  9. 9.
    Rinne JO, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ (1995) Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol 37:568–573PubMedCrossRefGoogle Scholar
  10. 10.
    Otsuka M, Kuwabara Y, Ichiya Y et al (1997) Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with 18F-dopa and 18F-FGD. Ann Nucl Med 11:251–257PubMedCrossRefGoogle Scholar
  11. 11.
    Gilman S, Koeppe RA, Junck L et al (1999) Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography. Ann Neurol 45:769–777PubMedCrossRefGoogle Scholar
  12. 12.
    Pirker W, Asenbaum S, Bencsits G et al (2000) [123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158–1167PubMedCrossRefGoogle Scholar
  13. 13.
    Kim GM, Kim SE, Lee WY (2000) Preclinical impairment of the striatal dopamine transporter system in sporadic olivopontocerebellar atrophy: studied with [123I]β-CIT and SPECT. Eur Neurol 43:23–29PubMedCrossRefGoogle Scholar
  14. 14.
    Lu CS, Weng YH, Chen MC et al (2004) 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 45:49–55PubMedGoogle Scholar
  15. 15.
    Jellinger KA, Seppi K, Wenning GK (2005) Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20:S29–S36PubMedCrossRefGoogle Scholar
  16. 16.
    Ozawa T, Paviour D, Quinn NP et al (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Esteban Muñoz
    • 1
  • Alex Iranzo
    • 2
  • Sebastian Rauek
    • 1
  • Francisco Lomeña
    • 3
  • Judith Gallego
    • 4
  • Doménec Ros
    • 4
  • Joan Santamaría
    • 2
  • Eduardo Tolosa
    • 1
  1. 1.Parkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències (ICN), Hospital Clínic i UniversitariInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED)BarcelonaSpain
  2. 2.Sleep Disorders Unit, Neurology Service, ICN, Hospital Clínic i UniversitariIDIBAPS, CIBERNEDBarcelonaSpain
  3. 3.Nuclear Medicine Service, Centre de Diagnòstic per la Imatge (CDI), Hospital Clínic i UniversitariInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
  4. 4.Biophysics Unit, Department of Physiological Sciences IBiomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBERBBN), University of BarcelonaBarcelonaSpain

Personalised recommendations